Therapeutic drug monitoring in peritoneal dialysis: A case of nontuberculous mycobacterium catheter‐related infection treated with amikacin | Zendy

Kojya Sanae | Zendy; Shiohira Hideo | Zendy; Sunagawa Yoshitsugu | Zendy; Tsuneyoshi Shoji | Zendy; Kohagura Kentaro | Zendy; Ohya Yusuke | Zendy; Yonaha Fusako | Zendy; Hokama Nobuo | Zendy; Nakamura Katsunori | Zendy

Open Access

Therapeutic drug monitoring in peritoneal dialysis: A case of nontuberculous mycobacterium catheter‐related infection treated with amikacin

Author(s) -

Kojya Sanae,

Shiohira Hideo,

Sunagawa Yoshitsugu,

Tsuneyoshi Shoji,

Kohagura Kentaro,

Ohya Yusuke,

Yonaha Fusako,

Hokama Nobuo,

Nakamura Katsunori

Publication year - 2020

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.2774

Subject(s) - medicine , amikacin , continuous ambulatory peritoneal dialysis , therapeutic drug monitoring , peritoneal dialysis , pharmacokinetics , dosing , catheter , dialysis , drug , intensive care medicine , surgery , pharmacology , antibiotics , microbiology and biotechnology , biology

The pharmacokinetics of amikacin makes it difficult to predict the appropriate dosing to avoid harmful side effects in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). The implementation of therapeutic drug monitoring may be useful in controlling amikacin serum concentrations in patients receiving CAPD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research